Neuberger Berman Group’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
Neuberger Berman Group's DNTH Position: Q3 2026 in Review
Neuberger Berman Group reduced its Dianthus Therapeutics (DNTH) stake by 49% in Q3 2026, selling an estimated $8.01M and leaving 80,434 shares worth $7.08M. The position accounts for ﹤0.01% of the portfolio, ranked #956.
Neuberger Berman Group first reported a position in DNTH in Q4 2025 and has held it in 4 quarters since. The position peaked at $15.4M in Q2 2026. 274 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- Neuberger Berman Group held 80,434 shares of Dianthus Therapeutics worth $7.08M as of Q3 2026.
- Neuberger Berman Group sold 77,140 Dianthus Therapeutics shares in Q3 2026, an estimated $8.01M.
- Dianthus Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q3 2026, its #956 holding.
- Neuberger Berman Group first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Neuberger Berman Group's Dianthus Therapeutics position peaked at $15.4M in Q2 2026.
- 274 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on Neuberger Berman Group's 13F filing for Q3 2026, filed 13 Nov 2026.